Cargando…
Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125
Cancer antigen 125 (CA125) is a widely used biomarker in monitoring of epithelial ovarian cancer (EOC). Due to insufficient cancer specificity of CA125, its diagnostic use is severely compromised. Abnormal glycosylation of CA125 is a unique feature of ovarian cancer cells and could improve different...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442799/ https://www.ncbi.nlm.nih.gov/pubmed/32826955 http://dx.doi.org/10.1038/s42003-020-01191-x |
_version_ | 1783573506581069824 |
---|---|
author | Bayoumy, Sherif Hyytiä, Heidi Leivo, Janne Talha, Sheikh M. Huhtinen, Kaisa Poutanen, Matti Hynninen, Johanna Perheentupa, Antti Lamminmäki, Urpo Gidwani, Kamlesh Pettersson, Kim |
author_facet | Bayoumy, Sherif Hyytiä, Heidi Leivo, Janne Talha, Sheikh M. Huhtinen, Kaisa Poutanen, Matti Hynninen, Johanna Perheentupa, Antti Lamminmäki, Urpo Gidwani, Kamlesh Pettersson, Kim |
author_sort | Bayoumy, Sherif |
collection | PubMed |
description | Cancer antigen 125 (CA125) is a widely used biomarker in monitoring of epithelial ovarian cancer (EOC). Due to insufficient cancer specificity of CA125, its diagnostic use is severely compromised. Abnormal glycosylation of CA125 is a unique feature of ovarian cancer cells and could improve differential diagnosis of the disease. Here we describe the development of a quantitative lateral flow immunoassay (LFIA) of aberrantly glycosylated CA125 which is widely superior to the conventional CA125 immunoassay (CA125IA). With a 30 min read-out time, the LFIA showed 72% sensitivity, at 98% specificity using diagnostically challenging samples with marginally elevated CA125 (35–200 U/mL), in comparison to 16% sensitivity with the CA125IA. We envision the clinical use of the developed LFIA to be based on the substantially enhanced disease specificity against the many benign conditions confounding the diagnostic evaluation and against other cancers. |
format | Online Article Text |
id | pubmed-7442799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-74427992020-09-02 Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125 Bayoumy, Sherif Hyytiä, Heidi Leivo, Janne Talha, Sheikh M. Huhtinen, Kaisa Poutanen, Matti Hynninen, Johanna Perheentupa, Antti Lamminmäki, Urpo Gidwani, Kamlesh Pettersson, Kim Commun Biol Article Cancer antigen 125 (CA125) is a widely used biomarker in monitoring of epithelial ovarian cancer (EOC). Due to insufficient cancer specificity of CA125, its diagnostic use is severely compromised. Abnormal glycosylation of CA125 is a unique feature of ovarian cancer cells and could improve differential diagnosis of the disease. Here we describe the development of a quantitative lateral flow immunoassay (LFIA) of aberrantly glycosylated CA125 which is widely superior to the conventional CA125 immunoassay (CA125IA). With a 30 min read-out time, the LFIA showed 72% sensitivity, at 98% specificity using diagnostically challenging samples with marginally elevated CA125 (35–200 U/mL), in comparison to 16% sensitivity with the CA125IA. We envision the clinical use of the developed LFIA to be based on the substantially enhanced disease specificity against the many benign conditions confounding the diagnostic evaluation and against other cancers. Nature Publishing Group UK 2020-08-21 /pmc/articles/PMC7442799/ /pubmed/32826955 http://dx.doi.org/10.1038/s42003-020-01191-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Bayoumy, Sherif Hyytiä, Heidi Leivo, Janne Talha, Sheikh M. Huhtinen, Kaisa Poutanen, Matti Hynninen, Johanna Perheentupa, Antti Lamminmäki, Urpo Gidwani, Kamlesh Pettersson, Kim Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125 |
title | Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125 |
title_full | Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125 |
title_fullStr | Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125 |
title_full_unstemmed | Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125 |
title_short | Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125 |
title_sort | glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum ca125 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442799/ https://www.ncbi.nlm.nih.gov/pubmed/32826955 http://dx.doi.org/10.1038/s42003-020-01191-x |
work_keys_str_mv | AT bayoumysherif glycovariantbasedlateralflowimmunoassaytodetectovariancancerassociatedserumca125 AT hyytiaheidi glycovariantbasedlateralflowimmunoassaytodetectovariancancerassociatedserumca125 AT leivojanne glycovariantbasedlateralflowimmunoassaytodetectovariancancerassociatedserumca125 AT talhasheikhm glycovariantbasedlateralflowimmunoassaytodetectovariancancerassociatedserumca125 AT huhtinenkaisa glycovariantbasedlateralflowimmunoassaytodetectovariancancerassociatedserumca125 AT poutanenmatti glycovariantbasedlateralflowimmunoassaytodetectovariancancerassociatedserumca125 AT hynninenjohanna glycovariantbasedlateralflowimmunoassaytodetectovariancancerassociatedserumca125 AT perheentupaantti glycovariantbasedlateralflowimmunoassaytodetectovariancancerassociatedserumca125 AT lamminmakiurpo glycovariantbasedlateralflowimmunoassaytodetectovariancancerassociatedserumca125 AT gidwanikamlesh glycovariantbasedlateralflowimmunoassaytodetectovariancancerassociatedserumca125 AT petterssonkim glycovariantbasedlateralflowimmunoassaytodetectovariancancerassociatedserumca125 |